Efficacy of Losartan within a Multicomponent Secondary Prevention Strategy for Cardiovascular Events in Post-Ischemic Stroke Patients

DOI: https://doi.org/10.63181/ujcvs.2025.33(3).16-24
Keywords: Ischemic heart disease, generalized atherosclerosis, ischemic stroke, losartan, secondary prevention, MMP-2, MMP-9, IL-1β, PAI-1, TAFI, TNF-α

Abstract

Aim. To assess the efficacy of adding losartan to standard therapy in patients with ischemic heart disease (IHD) and polyvascular atherosclerosis following ischemic stroke as part of a multicomponent secondary prevention strategy over a 4-month treatment period.

Materials and Methods. A prospective study enrolled 60 patients who were randomly assigned to two equal groups: standard therapy (including antiplatelet agents, statins, antihypertensive medications, and risk factor management) and standard therapy plus losartan. All patients underwent assessment of lipid profiles, as well as serum levels of the matrix metalloproteinases MMP-2 and MMP-9, interleukin-1β (IL-1β), plasminogen activator inhibitor-1 (PAI-1), thrombin-activatable fibrinolysis inhibitor (TAFI), and tumor necrosis factor-alpha (TNF-α), both at baseline and after 4 months of therapy.

Results. After 4 months of therapy, a significant reduction in the serum levels of lipids (TC, TG, LDL-C, HDL-C), MMP-2, MMP-9, IL-1β, PAI-1, TAFI, and TNF-α (p<0.05) was observed in both groups. However, compared with the standard therapy group, the addition of losartan was associated with a significant reduction in MMP-2 (p = 0.008) and TAFI (p = 0.011) in the intergroup ANCOVA analysis.

Conclusions. The addition of losartan to standard therapy in patients with IHD and polyvascular atherosclerosis following ischemic stroke over a 4-month period was associated with improved clinical outcomes, attenuation of inflammatory and proteolytic cascade activation, and enhanced hemodynamic parameters.

References

  1. O’Donnell MJ, Chin SL, Rangarajan S, Xavier D, Liu L, Zhang H, et al. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. Lancet. 2016;388:761–75. Available from: https://doi.org/10.1016/S0140-6736(16)30506-2
  2. Ge L, Zhang G, You B, Cheng G, Chen L, Shi R. The role of losartan in preventing vascular remodeling in spontaneously hypertensive rats by inhibition of the H2O2/VPO1/HOCl/MMPs pathway. Biochem Biophys Res Commun. 2017;493:855–61. Available from: https://doi.org/10.1016/J.BBRC.2017.06.026
  3. Sica DA, Weber M. The Losartan Intervention for Endpoint Reduction (LIFE) Trial—Have Angiotensin‐Receptor Blockers Come of Age? J Clin Hypertens. 2007;4:301. Available from: https://doi.org/10.1111/J.1524-6175.2002.01099.X
  4. Sgarra L, Desantis V, Matteucci A, Caccavo VP, Troisi F, Di Monaco A, et al. Non-Anticoagulation Strategies Aimed at Primary Stroke Prevention in Nascent Atrial Fibrillation. Biomedicines. 2025;13:660. Available from: https://doi.org/10.3390/BIOMEDICINES13030660
  5. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, De Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet. 2002;359:995–1003. Available from: https://doi.org/10.1016/S0140-6736(02)08089-3
  6. Ekholm M, Kahan T. The Impact of the Renin-Angiotensin-Aldosterone System on Inflammation, Coagulation, and Atherothrombotic Complications, and to Aggravated COVID-19. Front Pharmacol. 2021;12:640185. Available from: https://doi.org/10.3389/FPHAR.2021.640185
  7. Saravi B, Li Z, Pfannkuche J, Wystrach L, Häckel S, Albers CE, et al. Angiotensin II Type 1 Receptor Antagonist Losartan Inhibits TNF-α-Induced Inflammation and Degeneration Processes in Human Nucleus Pulposus Cells. Appl Sci. 2021;11:417. Available from: https://doi.org/10.3390/APP11010417
  8. Society for Vascular Ultrasound. SVU Professional Performance Guidelines. [Internet]. [cited 2025 Aug 25]. Available from: https://www.svu.org/practice-resources/professional-performance-guidelines/?utm_source
  9. Aydin S. A short history, principles, and types of ELISA, and our laboratory experience with peptide/protein analyses using ELISA. Peptides. 2015;72:4–15. Available from: https://doi.org/10.1016/j.peptides.2015.04.012
  10. Vos MB, Van Natta ML, Blondet NM, Dasarathy S, Fishbein M, Hertel P, et al. Randomized placebo-controlled trial of losartan for pediatric NAFLD. Hepatology. 2022;76:429–44. Available from: https://doi.org/10.1002/HEP.32403
  11. AlSaad AMS, Alasmari F, Abuohashish HM, Mohany M, Ahmed MM, Al-Rejaie SS. Renin angiotensin system blockage by losartan neutralize hypercholesterolemia-induced inflammatory and oxidative injuries. Redox Rep. 2020;25:51–8. Available from: https://doi.org/10.1080/13510002.2020.1763714
  12. Liu Q, Dong S, Zhou X, Zhao Y, Dong B, Shen J, et al. Effects of Long-Term Intervention with Losartan, Aspirin and Atorvastatin on Vascular Remodeling in Juvenile Spontaneously Hypertensive Rats. Molecules. 2023;28:1844. Available from: https://doi.org/10.3390/MOLECULES28041844
  13. Torvi A, D P, S S, Patil L. A Comparative Study of Tolerability of Losartan versus Atenolol in Essential Hypertension and Their Effect on Lipid Profile. Pharmacol Clin Pharm Res. 2021;6:122–30. Available from: https://doi.org/10.15416/PCPR.V6I3.32831
  14. Fogari R, Mugellini A, Zoppi A, Corradi L, Preti P, Lazzari P, et al. Losartan and perindopril effects on plasma plasminogen activator inhibitor-1 and fibrinogen in hypertensive type 2 diabetic patients. Am J Hypertens. 2002;15:316–20. Available from: https://doi.org/10.1016/S0895-7061(01)02340-8
  15. Suganuma E, Niimura F, Matsuda S, Ukawa T, Nakamura H, Sekine K, et al. Losartan attenuates the coronary perivasculitis through its local and systemic anti-inflammatory properties in a murine model of Kawasaki disease. Pediatr Res. 2016;81:593–600. Available from: https://doi.org/10.1038/pr.2016.266
  16. Wang X, Chen X, Huang W, Zhang P, Guo Y, Körner H, et al. Losartan suppresses the inflammatory response in collagen-induced arthritis by inhibiting the MAPK and NF-κB pathways in B and T cells. Inflammopharmacology. 2019;27:487–502. Available from: https://doi.org/10.1007/S10787-018-0545-2
  17. Guo YS, Zhang Q, Li JY, Liu Y, Sun T, He ZM, et al. Impact of losartan and angiotensin II on the expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in rat vascular smooth muscle cells. Mol Med Rep. 2014;11(3):1587-94. Available from: https://doi.org/10.3892/mmr.2014.2952
  18. Liang C, Wu ZG, Ding J, Jiang JF, Huang GZ, Du RZ, Ge JB. Losartan inhibited expression of matrix metalloproteinases in rat atherosclerotic lesions and angiotensin II-stimulated macrophages. Acta Pharmacol Sin. 2004;25(11):1426-32. PMID: 15525463. Available from: https://pubmed.ncbi.nlm.nih.gov/15525463/
  19. Bryniarski P, Nazimek K, Marcinkiewicz J. Immunomodulatory Activity of the Most Commonly Used Antihypertensive Drugs—Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers. Int J Mol Sci. 2022;23:1772. Available from: https://doi.org/10.3390/IJMS23031772
Published
2025-09-25
How to Cite
1.
Halich V-SM, Kobyliak NM, Pletenetska AO. Efficacy of Losartan within a Multicomponent Secondary Prevention Strategy for Cardiovascular Events in Post-Ischemic Stroke Patients. ujcvs [Internet]. 2025Sep.25 [cited 2025Oct.9];33(3):16-4. Available from: https://www.cvs.org.ua/index.php/ujcvs/article/view/750
Issue
Ukrainian Journal of Cardiovascular Surgery Vol 33 No 3 2025
Section
ISCHEMIC HEART DISEASE